TY - JOUR
T1 - Phase II study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma
AU - Kasahara, Senji
AU - Hara, Takeshi
AU - Tsurumi, Hisashi
AU - Goto, Naoe
AU - Kitagawa, Jun Ichi
AU - Kanemura, Nobuhiro
AU - Yoshikawa, Takeshi
AU - Goto, Hideko
AU - Fukuno, Kenji
AU - Yamada, Toshiki
AU - Sawada, Michio
AU - Takahashi, Takeshi
AU - Takami, Tsuyoshi
AU - Moriwaki, Hisataka
PY - 2011/4
Y1 - 2011/4
N2 - The anthracycline drug pirarubicin (tetrahydropyranyl adriamycin; THP) apparently has fewer cardiotoxic effects than doxorubicin. We previously described the benefit of the THP-COP regimen comprising cyclophosphamide, THP, vincristine, and prednisolone for elderly patients with diffuse large B-cell lymphoma (DLBCL). However, that study was completed before rituximab (R) was introduced into clinical practice. Here we report a phase II study of the THP-COP regimen combined with R (R-THP-COP) every 3 weeks. The complete response and 3-year overall survival rates was 63% and 53%, respectively, and no deaths were related to the regimen. We conclude that the R-THP-COP regimen is safe and effective for patients with DLBCL. Based on these results, a randomized controlled trial of rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) and R-THP-COP as a phase III study is ongoing.
AB - The anthracycline drug pirarubicin (tetrahydropyranyl adriamycin; THP) apparently has fewer cardiotoxic effects than doxorubicin. We previously described the benefit of the THP-COP regimen comprising cyclophosphamide, THP, vincristine, and prednisolone for elderly patients with diffuse large B-cell lymphoma (DLBCL). However, that study was completed before rituximab (R) was introduced into clinical practice. Here we report a phase II study of the THP-COP regimen combined with R (R-THP-COP) every 3 weeks. The complete response and 3-year overall survival rates was 63% and 53%, respectively, and no deaths were related to the regimen. We conclude that the R-THP-COP regimen is safe and effective for patients with DLBCL. Based on these results, a randomized controlled trial of rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) and R-THP-COP as a phase III study is ongoing.
UR - http://www.scopus.com/inward/record.url?scp=79953165380&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79953165380&partnerID=8YFLogxK
U2 - 10.3109/10428194.2011.555024
DO - 10.3109/10428194.2011.555024
M3 - Article
C2 - 21438831
AN - SCOPUS:79953165380
SN - 1042-8194
VL - 52
SP - 629
EP - 634
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 4
ER -
